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Abstract 
Purpose: To determine whether different coagulation-balance genetic 
polymorphisms explain the variable clinical outcomes of photodynamic 
therapy with verteporfin (PDT-V) in Caucasian patients with classic or 
predominantly classic choroidal neovascularization (CNV) due to age-
related macular degeneration (AMD). 
Methods: The clinical records of consecutive AMD patients with classic 
or predominantly classic CNV, treated with PDT-V according to the 
Treatment of Age-Related Macular Degeneration with Photodynamic 
Therapy study criteria, were retrospectively examined. Eighty-six eligible 
patients were subdivided in responder and non-responder basing on the 
modifications of best-corrected visual acuity between baseline and 12-
month checks. Six gene polymorphisms, i.e. factor V G1691A, 
prothrombin G20210A, factor XIII-A G185T, methylenetetrahydrofolate 
reductase C677T, methionine synthase A2756G, and methionine 
synthase reductase A66G, were genotyped in each patient. Binary logistic 
regression models were used to explore the predictive role of phenotypic 
and genotypic variables for PDT-V effectiveness. 
Results: PDT-V responders were more prevalent among the combined 
carriers for factor V 1691A and prothrombin 20210A alleles (OR = 5.1 
with a 95% CI of 1.0-24.4; P = 0.05), methylenetetrahydrofolate 
reductase 677 T-allele (OR = 4.3 with a 95% CI of 1.8-10.8; P = 0.002), 
and methionine synthase reductase 66 G-allele (OR = 2.8 with a 95% CI 
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of 1.1-6.8; P = 0.04). Conversely, PDT-V non-responders were over-
represented in patients with factor XIII-A 185 T-allele (OR = 0.22 with a 
95% CI of 0.09-0.56; P = 0.001). The other considered predictors did not 
significantly modify PDT-V effectiveness. 
Conclusion: Our study provides evidences for the presence of 
pharmacogenetic relationship between peculiar coagulation-balance gene 
polymorphisms and different levels of visual prognosis at 12 months in 
AMD patients treated with standardized PDT-V protocol for classic 
subfoveal CNV. 
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Abstract 
Scopo: determinare la correlazione tra differente polimorfismo dei geni 
della coagulazione e i diversi risultati clinici della terapia fotodinamica 
con verteporfina (PDT-V) in pazienti di razza caucasica affetti da 
degenerazione maculare legata all'età (DMLE) complicata da 
neovascolarizzazione coroideale (CNV) di tipo classico 
Metodo: Sono state esaminate le cartelle cliniche di ottantasei pazienti 
consecutivi con DMLE classica trattati con PDT-V secondo le linee 
guida del Treatment of Age-Related Macular Degeneration with 
Photodynamic Therapy study. I pazienti eleggibili allo studio sono stati 
suddivisi in responder e non-responder basandosi sui miglioramenti della 
acuita’ visiva tra il basaline ed il controllo a 12 mesi. Sei polimorfismi 
del gene sono stati analizzati in ciascun paziente: fattore V G1691A, 
protrombina G20210A, Fattore XIII-A G185T, metilentetraidrofolato 
reduttasi C677T, metionina sintetasi A2756G, e metionina sintetasi 
reduttasi A66G. Il campione e’ stato analizzato con il modello binario di 
regressione logistica per valutare l’efficacia della PDT-V in base alle 
variabili fenotipiche e genotipiche. 
Risultati: i pazienti PDT-V responders presentavano fattore V 1691A e  
alleli 20210A protrombina (OR = 5.1, con un IC 95% 1,0-24,4; P = 
0,05), metilentetraidrofolato reduttasi 677 T-allele (OR = 4,3 con un IC 
95% di 1,8-10,8; P = 0,002), e la metionina reduttasi sintasi 66 G-allele 
(OR = 2,8, con un IC 95% di 1,1 - 6,8, P = 0,04). Al contrario, i pazienti 
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PDT-V non-responders alla V presentavano fattore XIII-A 185 T-allele 
(OR = 0,22 con un CI del 95% di 0,09-0,56, P = 0.001). Gli altri fattori 
considerati non modificavano sostanzialmente l'efficacia PDT-V.  
Conclusioni: Il nostro studio fornisce evidenze della presenza di un 
rapporto farmacogenetico tra il polimorfismo dei geni della coagulazione 
e diversi livelli di prognosi visiva a 12 mesi nei pazienti trattati con 
terapia fotodinamica per degenerazione maculare legata all'età 
complicata da neovascolarizzazione coroideale di tipo classico.
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Introduction 
Choroidal neovascularization (CNV) beneath the fovea represents a 
common cause of central blindness or low-vision in Caucasian 
populations affected by age-related macular degeneration (AMD) 
(ARMD1 [MIM 603075]). 1, 2 Although intravitreal drugs acting against 
vascular endothelial growth factor (anti-VEGF) have recently shown a 
remarkable potential towards several ocular diseases complicated by 
aberrant angiogenesis, 3-6 photodynamic therapy with verteporfin (PDT-
V) still remains an evidence-based treatment that maybe realizes the 
inactivation of AMD-related subfoveal CNV. 6-8 Experimental and 
clinical evidences indicate that the combined use of both these strategies 
is the most promising therapeutic approach towards this harmful disease. 
9-14 
The therapeutic effect of PDT-V is achieved by a laser-light-induced 
thrombosis of CNV, which has been previously photosensitized by the 
administration of verteporfin (benzoporphyrin derivative monoacid A). 
15-19 PDT-V for CNV is currently performed as indicated by the protocol 
utilizing in the Treatment of Age-Related Macular Degeneration with 
Photodynamic Therapy (TAP) and the Visudyne in Photodynamic 
Therapy (VIP) studies. 7, 20, 21 Standardized PDT-V consists of a 6 mg/m2 
dose of liposomal verteporfin formulation intravenously infused over 10 
minutes, and a light dose of 50 J/cm2 delivered over a period of 83 
seconds; the time for the low-intensity, non-thermal laser irradiation 
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(light at a wavelength of 689 nm and an irradiance of 600 mW/cm2) was 
15 minutes after the start of verteporfin injection; the diameter of the 
irradiated area corresponds to the greatest linear dimension (GLD) of 
CNV added to 1000 micron to provide a 500 micron safety margin all-
around the lesion. 20, 21 The PDT-V mechanism of action has been 
initially considered ideal for the treatment of subfoveal CNV. 15 
However, the individually variable efficacy of standardized PDT-V is 
clearly noticeable reviewing the outcomes of TAP, VIP, and Visudyne in 
Minimally Classic Choroidal Neovascularization studies. In fact, the 
rather proportioned percentage of cases with or without severe visual loss 
after PDT-V is evident for all the AMD-related forms of CNV. 6, 20-22 
Moreover, differences in CNV responsiveness to standardized PDT-V 
between Asian and Caucasian patients have been recently pointed out. 23, 
24 Despite both these evidences of individual and racial variability, and 
the well-known therapeutic PDT-V effect aimed at the photo-thrombotic 
perturbation of hemostasis within the neovascular complex, 15-19 the 
predictors of visual acuity modifications in AMD patients treated with 
verteporfin-therapy protocol have been hitherto examined without 
considering the role of coagulation-balance genetic backgrounds in 
changing its effectiveness. 25-29 Several gene variations can affect the 
balance between pro- and anti-coagulant mechanisms, accounting for the 
occurrence of thrombophilic or hemorrhagic diatheses. 30-40 Once 
thrombo-coagulative process starts, physiologically or therapeutically 
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triggered, both anticoagulation and fibrinolysis are involved to limit and 
regulate the thrombosis in the ill- or treated-area. A non-optimal restoring 
of the hemostatic balance is able to cause abnormalities in thrombus 
formation or dissolution. Recently, in patients with AMD complicated by 
classic and occult CNV, we have documented the presence of predictive 
correlations between peculiar mutated alleles modulating the thrombo-
fibrinolytic equilibrium and different angiographic levels of short-term 
responsiveness to PDT-V. 41, 42 
The aim of this study was to investigate several single nucleotide 
polymorphisms (SNPs), encoding enzymes involved in the coagulative 
process, as predictors of the difference in visual acuity after a 12-month 
PDT-V protocol, carried out in Caucasian AMD patients with classic 
subfoveal CNV. In particular, the post-operative long-term variability of 
this clinical parameter was evaluated considering its putative association 
with common or uncommon gene variants, schematically shared in two 
typologies: i. gain-of-function SNPs directly influencing the coagulation 
cascade, i.e. factor V Leiden (FVL-G1691A), prothrombin G20210A 
(FII-G20210A), and factor XIII-A G185T (FXIIIA-G185T); 31-35 ii. SNPs 
modulating homocysteine (Hcy) metabolism, which indirectly affect the 
hemostatic balance, i.e. methylenetetrahydrofolate reductase C677T 
(MTHFR-C677T), methionine synthase A2756G (MS-A2756G) and 
methionine synthase reductase A66G (MTRR-A66G). 36-40 
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Methods 
We conducted a retrospective analysis of the clinical records of 
Caucasian patients with AMD complicated by new-diagnosed, subfoveal, 
classic or predominantly classic CNV, and exclusively treated with 
TAP/VIP-standardized verteporfin protocol during a 12-month follow-up 
period. The diagnosis of exudative AMD was based on the criteria of the 
International ARM Epidemiological Study Group. 43 The classification of 
CNV was based on the definitions from TAP/VIP Study Groups. 20, 21 All 
patients underwent, within two weeks after the onset of CNV-related 
visual symptoms, both fluorescein angiography (FA) and indocyanine 
green angiography (ICGA) to well-detail the presence of AMD-related 
subfoveal CNV. For the purposes of this study, AMD patients were 
consecutively selected to achieve a consistent study cluster of, at least, 80 
cases. Each course of standardized PDT-V was performed within 7 days 
from diagnosis or follow-up angiographies in reference to the published 
guidelines for standardized PDT-V application (TAP/VIP protocol). 7 
The patients were evaluated at 3-month intervals for one year; additional 
courses of treatment were achieved in case of persistence of fluorescein 
leakage from the CNV according to TAP/VIP criteria. 20, 21 During all 
clinical examinations, patients underwent medical and ophthalmologic 
histories, auto-refraction, best-correct visual acuity (BCVA), slit-lamp 
biomicroscopy, applanation tonometry, 60-diopter lens ophthalmoscopy, 
and FA. Snellen BCVA was measured using a standard logarithmic chart 
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at a test distance of three meters. Each BCVA datum was converted to 
the logarithm of the minimum angle of resolution (logMAR) scale for 
statistical analyses. FA and ICGA were performed employing IMAGEnet 
digitizing system (Topcon Corp., Japan). After angiographic 
examinations, the CNV area (mm2) was directly measured on angiograms 
using the software available into IMAGEnet package. In the course of a 
masked retrospective assessment, each patient was considered responder 
or non-responder to PDT-V quoting the BCVA difference calculated 
between final and baseline values: post-PDT-V BCVA – pre-PDT-V 
BCVA. These data were recorded, respectively, after 12 months ± 1 
week from the first PDT-V and 7 or less days before the first PDT-V. At 
the end of follow-up period, patients with a BCVA decrease greater than 
0.1 logMAR were arbitrarily defined non-responder, whereas the cases 
with minor vision loss, as well as those characterized by stabilization or 
improvement of BCVA were labeled as responder. 
Inclusion and exclusion criteria are listed in Table 1. All the enrolled 
patients gave their written informed consent to participate to the study, 
after a detailed description of the aim-work and of the procedures to be 
used. The local Ethic Committee reviewed and approved the clinical trial. 
The study followed the tenets of the Declaration of Helsinki. Since the 
typology of the investigated clinical parameters, the sample size 
calculation, accomplished for the amount of study population (86 cases), 
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has provided a value constantly upper than 85%. This test was performed 
using the PASS 97 statistical program (NCSS Inc., Kaysville, UT, USA). 
Blood samples were collected for the SNPs genotyping prior to the first 
PDT-V application. Genomic DNA was isolated from peripheral blood 
by using standard proteinase K treatment, followed by phenol-chloroform 
extraction and ethanol precipitation. Samples were polymerase chain 
reaction (PCR)-genotyped for FVL-G1691A, FII-G20210A, FXIIIA-
G185T, MTRR-A66G, MS-A2756G, and MTHFR-C677T gene variants, 
according to previous reports of Gemmati and co-workers. 44-46 
Genotypes were confirmed by re-genotyping a random selection of 
samples for each polymorphism investigated. There were no 
discrepancies between genotypes determined in duplicate. Genotyping 
was carried out in a blinded fashion relative to the clinical phenotype of 
patients. The expected allele frequencies in the whole group of 
investigated cases were checked by the Hardy-Weinberg equilibrium test 
for those SNPs showing a rate < 5% and compared with a cluster of 
normal subjects. They were matched for sex, age and ethnicity with the 
case group. 
One-way, repeated-measures analysis of variance was used to assess the 
modifications of both BCVA and CNV area within follow-up times. 
Odds ratios (OR) and 95% confidence intervals (CI) were used to 
estimate the probability of belonging to responder or non-responder to 
PDT-V. Adjusted ORs for single or combined comparisons were 
 11 
calculated with binary logistic regression models, controlled for sex and 
age. Thus, univariate and multivariate analyses were performed to 
determine which variables were predictive of PDT-V responder, using 
responder/non-responder as dependent binary variable. In these 
regression models, the putative predictors were included according to the 
clinical plausibility of their possible influence on the dependent variable. 
The following parameters were considered as PDT-V predictors: 
patient’s age, pre-PDT-V BCVA, pre-PDT-V CNV area, FVL-1691 
GA/AA, FII-20210 GA/AA, FXIIIA-185 GT/TT, MTRR-66 AG/GG, 
MS-2756 AG/GG, and MTHFR-677 CT/TT. Those putative predictors 
that did not significantly contribute to the univariate logistic regression 
were ruled out from all the final multivariate selected regression models 
(exclusion threshold, P > 0.10). All analyses were performed by Systat 
V.5.0 All analyses were performed by Systat V.5.0 (Systat Inc., 
Evanston, IL, USA) and SPSS Statistical Package (SPSS Inc., Chicago, 
IL, USA). A probability of P < 0.05 was considered statistically 
significant. 
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Table 1. Inclusion and exclusion criteria. 
 
Inclusion criteria 
- patient’s age > 65 years 
- diagnosis of AMD 
- best-correct visual acuity better than 20/200 (Snellen equivalent) 
- FA/ICGA signs of classic or predominantly classic CNV secondary to AMD 
- CNV under the geometric center of the foveal avascular zone (subfoveal) 
- greatest linear dimension of entire CNV less than 5400 micron 
Exclusion criteria 
- retinal photocoagulative treatment of the posterior pole before PDT-V 
- presence of any other possible cause of CNV, such as degenerative myopia, angioid streaks, 
chorioretinal inflammatory diseases, hereditary retinal disorders, presumed ocular histoplasmosis 
syndrome, and/or severe ocular trauma 
- intraocular surgery and any ocular laser-treatment during the 6 months before or the 3 months after 
PDT-V 
- presence of any significant side effect, condition and/or event influencing PDT-V outcome 
- active or chronic systemic diseases (such as porphyria, diabetes mellitus, hepatopathies, metabolic, 
cardiovascular, and hematological disorders), as well as assumption of any medication, known to 
affect the hemostatic balance 
- protein intake, during breakfast or lunch, occurred 12 hours before PDT-V 
 
Footnotes: AMD = age-related macular degeneration; FA = fluorescein angiography; 
ICGA = indocyanine green angiography; CNV= choroidal neovascularization;  
PDT-V = photodynamic therapy with verteporfin
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Results 
Demographic characteristics, pre- and post-PDT-V ophthalmologic data, 
and PDT-V-application attributes of the enrolled sample are summarized 
in Table 2. Over the follow-up period, mean BCVA moderately 
decreased from 0.68 to 0.82 logMAR, but an evident overlap between the 
upper bound of the baseline 95% CI and 95% CI lower bound at the 12th 
month was observable. Although a reduction of mean CNV area occurred 
(2.32 vs 1.43 mm2), it did not arrive at a significant rank at the end of the 
12-month follow-up period. In the present series of AMD patients with 
classic or predominantly classic CNV, the visual outcome was not as 
good as that reported by the TAP trial. 20 However, the 12-month mean 
change in BCVA of this investigated cluster (0.14 logMAR) is 
comparable to those observed in other clinical-setting studies, performed 
utilizing the same standardized PDT-V protocol in patients with 
analogous forms of AMD-related CNV. 47-50 
Genotype frequencies in total study cluster, as well as in responders and 
non-responders to PDT-V are reported in Table 3. Both FVL-G1691A 
and FII-G20210A showed an allele frequency < 5%. In the investigated 
case group, no significant deviations from Hardy-Weinberg equilibrium 
(all P values > 0.50) and from genotype distribution of a healthy control 
population were observed for these SNPs. In detail: i. FVL-G1691A – 
total cases n = 86; GG = 80; AG = 6; AA = 0 vs control group n = 100; 
GG = 97; GA = 3; AA = 0); ii. FII-G20210A – total cases n = 86; GG = 
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81; AG = 5; AA = 0 vs control group n = 100; GG = 98; GA = 2; AA = 
0). Genotype distributions of FVL-G1691A and FII-G20210A detected 
within our control cluster were in accordance with those previously 
reported in Caucasians. 30, 31, 44 Since both FVL 1691 and FII 20210 A-
alleles result in a well-known pro-coagulant predisposition in Caucasian 
subjects 31-33 and they are not so frequent as the other examined SNPs, 
these genetic variants have been also collectively analyzed (FVL-1691 
plus FII-20210 GA/AA) owing to the absence of concomitant-carrier 
case. 
The ORs, adjusted by univariate logistic regression for the probability 
estimation of clinical efficacy (responders) or inefficacy (non-
responders) of PDT-V, are shown in Table 4. When each phenotypic or 
genotypic factor was examined on univariate basis as putative PDT-V 
predictive covariate, FXIIIA 185-T carriers were more frequent within 
non-responders (OR = 0.22 [GT or TT vs GG], 95% CI: 0.09-0.56; P < 
0.001), hence this mutated genotypic trait was related to a higher risk of 
severe BCVA reduction at the end of 12-month, standardized, verteporfin 
therapy protocol. Conversely, the predictors of PDT-V clinical efficacy 
were, from the less to the more common: FVL-1691 plus FII-20210 
GA/AA (OR = 5.1 [AA or GA vs GG], 95% CI: 1.0-24.4; P = 0.05), 
MTRR-66 AG/GG (OR = 2.8 [AG or GG vs AA], 95% CI: 1.1-6.8; P = 
0.04), and MTHFR-677 CT/TT (OR = 4.3 [CT or TT vs CC], 95% CI: 
1.8-10.8; P = 0.002). All the other considered predictive factors did not 
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significantly modify the long-term BCVA modification after PDT-V 
application (Table 4). On selected multivariate analysis including factors 
with a univariate P-value ≤ 0.10, all the covariates, with the exception of 
pre-PDT-V CNV area and MTRR 66G-allele, still displayed influence on 
PDT-V outcome. In particular, both FVL-1691 plus FII-20210 GA/AA 
(OR = 8.5 [AA or GA vs GG], 95% CI: 1.3-54.1; P = 0.03) and MTHFR-
677 CT/TT (OR = 3.9 [CT or TT vs CC], 95% CI: 1.3-11.6; P = 0.02) 
were significantly over-represented among the cases with acceptable 
PDT-V response, whereas FXIIIA-185 GT/TT had a higher prevalence in 
patients with final marked vision loss (OR = 0.39 [GT or TT vs GG], 
95% CI: 0.1-0.9; P = 0.05) (Table 5). 
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Table 2. Demographic characteristics, pre- and post-PDT-V 
ophthalmologic data, and PDT-V-application attributes of the study 
group. 
n of patients 86 
Sex (males / females) (n) 39 / 47 
Age (mean ± SD; range) (years) 73.91 ± 6.48 (66-89) 
Pre-PDT-V CNV area (mean ± SD; range) (mm2) 2.32 ± 1.19 (0.4-5.1) 
Pre-PDT-V BCVA (mean ± SD; range) (logMAR) 0.68 ± 0.27 (0.1-1.0) 
Number of PDT-V (mean ± SD; range) 2.99 ± 0.81 (1-4) 
Post-PDT-V CNV area (mean ± SD; range) (mm2) 1.43 ± 2.11 (0.3-5.3) 
Post-PDT-V BCVA (mean ± SD; range) (logMAR) 0.82 ± 0.50 (0.1-2.0) 
Post-PDT-V BCVA – pre-PDT-V BCVA (mean ± SD; range) (logMAR) 0.14 ± 0.47 (– 0.8-1.7) 
PDT-V responder / non-responder 44 / 42 
 
Footnotes: SD = standard deviation; PDT-V = photodynamic therapy with verteporfin; 
CNV= choroidal neovascularization; mm = millimeter; BCVA= best-correct visual 
acuity; MAR = minimum angle of resolution;. 
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Table 3. Genotype frequencies in total study population, PDT-V responder and 
PDT-V non-responder groups. 
Single nucleotide 
polymorphism (genotype) 
Genotype frequency 
 Total study 
population 
(n = 86 cases) 
PDT-V responder 
group 
(n = 44 cases) 
PDT-V non-
responder group 
(n = 42 cases) 
FVL-G1691A (GG / GA / AA) 80 / 6 / 0 38 / 6 / 0 42 / 0 / 0 
FII-G20210A (GG / GA / AA) 81 / 5 / 0 41 / 3 / 0 40 / 2 / 0 
FVL-G1691A plus FII-
G20210A (GG / GA / AA) 
75 / 11 / 0 35 / 9 / 0 40 / 2 / 0 
FXIIIA-G185T (GG / GT /TT) 52 / 31 / 3 34 / 9 / 1 18 / 22 / 2 
MTHFR-C677T (CC /CT/ TT) 38 / 31 / 17 12 / 16 / 16 26 / 15 / 1 
MS-A2756G (AA / AG / GG) 65 / 21 / 0 34 / 10 / 0 31 / 11 / 0 
MTRR-A66G (AA / AG / GG) 31 / 36 / 19 11 / 21 / 12 20 / 15 / 7 
 
Footnotes: PDT-V = photodynamic therapy with verteporfin; FVL-G1691A = factor V Leiden; 
FII-G20210A = prothrombin G20210A; FXIIIA-G185T = factor XIII-A G185T; MTHFR-
C677T = methylenetetrahydrofolate reductase C677T; MS-A2756G = methionine synthase 
A2756G; MTRR-A66G = methionine synthase reductase A66G. 
 
 18 
 
Table 4. Summary of the univariate logistic regression analyses. 
 
Variable P OR (95% CI) 
Age NS NR 
Pre-PDT-V BCVA NS NR 
Pre-PDT-V CNV area NS NR 
FVL-G1691A (GA or AA) NS NR 
FII-G20210A (GA or AA) NS NR 
FVL-G1691A plus FII-G20210A (GA or AA) 0.05 5.1 (1.0-24.4) 
FXIIIA-G185T (GT or TT) 0.001 0.22 (0.09-0.56) 
MTHFR-C677T (CT or TT) 0.002 4.3 (1.8-10.8) 
MS-A2756G (AG or GG) NS NR 
MTRR-A66G (AG or GG) 0.04 2.8 (1.1-6.8) 
 
Footnotes: PDT-V = photodynamic therapy with verteporfin; BCVA= best-correct 
visual acuity; CNV= choroidal neovascularization; FVL-G1691A = factor V Leiden; 
FII-G20210A = prothrombin G20210A; FXIIIA-G185T = factor XIII-A G185T; 
MTHFR-C677T = methylenetetrahydrofolate reductase C677T; MS-A2756G = 
methionine synthase A2756G; MTRR-A66G = methionine synthase reductase A66G; 
OR = Odds ratio; CI = confidence interval; NS = not significant; NR = not relevant. 
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Table 5. Summary of the multivariate logistic regression analyses, including the 
variables with a univariate P-value ≤ 0.10. 
 
Variable P OR (95% CI) 
Pre-PDT-V CNV area NS NR 
FVL-G1691A plus FII-G20210A (GA or AA) 0.03 8.5 (1.3-54.1) 
FXIIIA-G185T (GT or TT) 0.05 0.39 (0.1-0.9) 
MTHFR-C677T (CT or TT) 0.02 3.9 (1.3-11.6) 
MTRR-A66G (AG or GG) NS NR 
 
Footnotes: PDT-V = photodynamic therapy with verteporfin; FVL-G1691A = factor V 
Leiden; FII-G20210A = prothrombin G20210A; FXIIIA-G185T = factor XIII-A 
G185T; MTHFR-C677T = methylenetetrahydrofolate reductase C677T; MTRR-A66G 
= methionine synthase reductase A66G; OR = Odds ratio; CI = confidence interval; NS 
= not significant; NR = not relevant. 
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Figure 1. Two cases of classic choroidal neovascularization (CNV) 
lesion treated with PDT-V. The angiogram shows a regression of 
choroidal neovascular activity pre (A) and post PDT-V treatment (B). 
 
 
 21 
21 
Discussion 
Several inherited or acquired clotting abnormalities are associated with a 
lopsided hemostasis. 30-40 The balancing of pro- and anti-coagulant 
processes has a key role in establishment and/or progression of 
thrombophilia, which can be defined as an increased tendency towards 
thrombosis induced by a multi-causal disorder wherein genetic and 
environmental factors interact dynamically. 30-31 The photothrombotic 
effect, obtained within the neovascular lesion following PDT-V 
application, is essentially due to a prevalent photosensitizer binding to 
the endothelium of CNV in comparison with that of normal macular 
vasculature. In blood circulation, the liposomally delivered verteporfin 
couples with plasma low density lipoproteins (LDL) to form a complex, 
which is then preferentially up-taken into neovascular endothelial cells 
via endocytosis for an overexpression of LDL receptors at CNV level. 
Intensive damage of neovascular endothelium induced by PDT-V results 
from the photo-oxidative action of several types of reactive oxygen 
species (ROS), representing the trigger that leads to therapeutic blood 
flow stasis and tissue hypoxia within CNV. These conditions can elicit a 
cascade of events (i.e. amplification of platelet activation, thrombosis, 
vasoconstriction, and increased vascular permeability), aimed at the final 
shutdown of CNV vasculature. 15 In accordance with the hypothesized 
work postulations, the present predictive findings indicate that the 
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mechanism of action of PDT-V is characterized by several phases which 
are strongly modifiable by peculiar coagulation-balance SNPs. 
Significant correlations were identified between satisfactory or 
unsatisfactory visual outcomes at the end of 12-month, TAP/VIP-
standardized verteporfin protocol and, respectively, thrombophilic or 
anti-thrombophilic genotypic predictors. In this pharmacogenetic 
investigative approach, retrospectively applied in Caucasian patients with 
AMD-related classic CNV, three crucial steps are involved in 
determining the clinical success of PDT-V, 15, 17, 19 and each of them 
appears to be dependent on particular genetic backgrounds: i. the 
triggering of photo-chemical damages at the level of neovascular 
endothelium is positively influenced by two common 
hyperhomocysteinemic gene variants, i.e. MTHFR-C677T and MTRR-
A66G; ii. the progressive photothrombotic closure of neovascular 
complex is enhanced by the FVL-1691 or by FII-20210 A-alleles, both 
predisposing to thrombotic diathesis and higher thrombin generation; iii. 
the persistence and the extensiveness of the hemodynamic occlusion 
within CNV are negatively affected by the hyperfibrinolytic FXIII-185 
T-allele. 
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i. Post-PDT-V damages of CNV endothelium and 
hyperhomocysteinemic gene polymorphisms 
At the level of CNV endothelium, the modalities by which PDT-V photo-
chemical action triggers the therapeutic pro-thrombotic process 15, 41, 51 
are largely overlapped with those occurring in the course of 
hyperhomocysteinemia (HHcy) owing to the presence of folate-related 
gene variants. 37, 39 These SNPs are able to cause appreciable enzymatic 
defects in MTHFR, MTRR and other enzymes, inducing endovascular 
damage via hyper-activation of endothelial cells and platelets. 38, 52 HHcy 
leads to thrombophilia as a result of ROS-related triggering, 53-55 which 
initiates lipid peroxidation in endothelial cell membranes and in 
circulating LDL, 36 overexpresses lectin-like oxidized LDL receptor-1, 56, 
57 and enhances platelet activation. 58 All these hyperhomocysteinemic 
effects, occurring in both MTHFR 677T-carriers and MTRR 66G-
carriers, 37, 39, 52 could play a key role in photodynamic therapeutic effect, 
strongly supporting the concept of a gene-environment interaction 
between PDT-V efficacy and thrombophilic SNPs affecting Hcy 
metabolism. 38, 40, 41 Therefore, the lower odds of post-PDT-V severe 
BCVA reduction at one year, recorded in carriers of 
hyperhomocysteinemic SNPs with AMD-related classic CNV, is 
attributable to a more effectual photo-oxidative activation during the first 
phases of CNV photothrombosis. 15, 38-41 Moreover, oxidation of LDL-
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vesicles in the sub-endothelial spaces may affect the uncoagulable 
properties of endothelium giving back basically a more activable surface 
responsible for local hyper-reactivity. 59 In the course of HHcy, an 
increased vascular oxidant stress has been shown to activate 
inflammatory signaling pathways in endothelial cells, like the 
transcriptional nuclear factor kappa B. 54 These items should be 
considered for a further possible explanation of the present results. In 
fact, inflammatory and oxidative damages are implicated during the 
nuclear factor kappa B activation in human endothelial cells after 
photodynamic therapy, 15, 60 suggesting a linear correlation between the 
efficacy of this treatment and these changes within the ill-treated area. 
 
ii. Post-PDT-V magnitude of CNV occlusion and gene 
polymorphisms affecting thrombin generation 
In patients with neovascular AMD, the sequence of early vascular events 
after PDT-V has been investigated using scanning laser system to 
achieve confocal FA and ICGA images for the evaluation of CNV size 
and leakage. These exams show that the photo-thrombotic occlusion of 
the entire CNV does not immediately take place, but it happens over a 
prolonged period of about 24 hours. 17 During this time course, pro-
coagulant, anti-coagulant and fibrinolytic factors may influence the 
extent of thrombo-coagulative process inside CNV. Thus, thrombophilic 
 25 
25 
gain-of-function SNPs can modify this photodynamic phase of CNV 
thrombosis. Both the uncommon SNPs G1691A of FV gene and 
G20210A of FII gene induce thrombophilia increasing the level of 
thrombin bio-availability in plasma. 31-33 FV is a cofactor enzyme with 
pivotal roles in hemostatic equilibrium especially stimulating the 
inactivation of factor VIIIa by activated protein C; in FV-1691A carriers, 
this anticoagulant function is altered with a consequent increased 
thrombin generation causing a pro-thrombotic state. 31, 32 Prothrombin is 
the central component of coagulation cascade which in its active form, 
thrombin, regulates both pro- and anti-coagulant processes; in FII-
20210A carriers the elevation of prothrombin expression is due to 
functional abnormalities of its mRNA metabolism, able to predispose to 
thrombosis affecting a tightly balanced architecture of non-canonical 3’ 
end formation signals. 31, 33 Consistently, as a consequence of their 
individual thrombophilic predisposition, the heterozygous A-allele 
carriers of FV 1691 or FII 20210 gene appear to be characterized by an 
higher possibility to exhibit clinical benefit after PDT-V owing to a 
greater magnitude of CNV photo-thrombosis. This correlation, also 
present on selected multivariate analysis, supports the pharmacogenetic 
suitability of the work postulations, even if it has not been observed 
considering FVL-G1691A and FII-G20210A polymorphisms alone, 
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probably because of their low prevalence in the Caucasian general 
population. 30, 31, 44 
 
iii. Post-PDT-V hemodynamic recanalization of CNV and 
hyperfibrinolytic gene polymorphisms 
In all AMD patients affected by subfoveal CNV and treated with 
verteporfin therapy, the three-dimensional analyses of retinochoroidal 
angiograms after PDT-V disclose several distinctive features of the “dark 
spot”, i.e. the typical circular hypofluorescence corresponding to the 
laser-exposed area. During the first hours following PDT-V, this 
angiographic pattern is only partially due to photo-thromboses of CNV 
and collateral choroid, which are also associated with a massive fluid 
extravasation. One week later, the slowly regression of exudation results 
in displaying the whole extent of photodynamic occlusive effects. 19 
However, this phase of blood non-perfusion is individually variable and, 
at 7-day check after PDT-V, the angiographic findings show that CNV 
vascular net is still apparent in about half of the treated patients. 18 This 
changeability in the post-PDT-V retinochoroidal appearance may be 
related to differences in fibrin structure, able to influence the fibrinolysis 
rate of each individual. 34, 35 Plasma coagulation factor XIII (FXIII) is 
directly involved in the final steps of coagulation cascade and indirectly 
in fibrinolytic process. It is the precursor of a transglutaminase that cross-
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links fibrin and, altering its network and properties, regulates fibrinolysis. 
The FXIII rate of activation is modulated by FXIIIA-G185T 
polymorphism, 35 a relatively common genetic variation among 
Caucasian population. 34 Both GT and TT genotypes are associated with 
remarkable modification in FXIII transglutaminase activity, which 
appears to be highly increased in homozygotes and exhibits an 
intermediate function in heterozygous carriers. 34 In the present study 
cluster, a reduced fibrin-clot stability and persistence, together with an 
increased fibrin-network permeability, could explain the correlation 
between this fibrinolytic-related polymorphism and the long-term 
inefficacy of the verteporfin protocol, owing to the early CNV 
recanalization after each PDT-V application. In this view, the very 
different frequency of FXIIIA 185T-allele among Caucasian and Asian 
races (respectively, 25-30% and close to 0%), 61, 62 could notionally 
explain the better outcomes obtained in Asians after verteporfin-therapy 
protocol. 23, 24 Otherwise, also the neo-angiogenic properties ascribed to 
FXIII may in part account for our predictive findings. In fact, a more 
active FXIII molecule at the site of injury (i.e. in the FXIII T-carriers) 
could downgrade PDT-V benefit by contrasting the laser-induced CNV 
deactivation. Our speculation is supported by the findings of 
neovascularization development after FXIIIA injection in experimental 
cornea model. 63 
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In Caucasian patients affected by AMD-related CNV and treated with 
standardized TAP/VIP protocol during a 12-month period, the present 
findings document the presence of predictive, gene-environment 
interactions between different levels of final visual outcome and several 
SNPs encoding enzymes involved in coagulation and/or fibrinolysis. 
Particularly, a satisfactory, post-PDT-V differential value of BCVA 
appears to be directly dependent on common folate-pathway gene 
variants (i.e. MTHFR-C677T and MTRR-A66G), which convert vascular 
endothelium and natural anticoagulant pathway to a more pro-thrombotic 
phenotype increasing plasma Hcy level, 36-40 consequently enhancing the 
post-PDT-V oxidative triggering of CNV endothelium. Likewise, an 
adequate visual result is also associated with the presence of rare 
thrombophilic SNPs (i.e. FV-1691A plus FII-20210A), able to increase 
the thrombin concentration and activation in plasma, 31-33 intensifying the 
magnitude of thrombosis within the neovascular complex. On the other 
hand, in carriers of common hyperfibrinolytic genotypes (i.e. FXIIIA-185 
GT or TT), which modify the polymerized fibrin structure affecting 
thrombin ability to effectively hydrolyze the factor XIII activation 
peptide, 34, 35 the most frequent occurrence of severe visual loss is 
reliably related to a minor persistence of hemodynamic CNV shutdown 
after each application of verteporfin therapy. These long-term results 
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resemble those previously reported by Parmeggiani and co-workers in 
another separate cluster of Caucasians with AMD-related classic CNV 
investigated for a 3-month follow-up period, 41 and definitely support the 
prospect to utilize, during the routine ophthalmologic practice, some 
pharmacogenetic predictors for the optimization of PDT-V application in 
either single or combined treatment modality. In fact, the clinical 
applicability of the present findings mainly concerns the opportunity to 
improve the eligibility criteria of TAP/VIP standardized PDT-V, 
currently centered just on the morphological composition of CNV. 6, 7, 25-
27 A pre-operative assessment of individual genetic backgrounds for 
designated coagulation-balance SNPs should make possible a more 
rational selection of candidates to PDT-V which, at present, is especially 
employed in combined treatment modalities. 9-14 This pharmacogenetic 
approach towards PDT-V predictors could rationally guide the 
interventional planning for exudative AMD: i. associating this CNV 
photo-thrombosis with anti-angiogenic therapy only in patients with 
thrombophilic diathesis that facilitates CNV photothrombosis; 15, 31-33, 36-
41, 59, 60 ii. preferentially choosing anti-VEGF drugs in carriers of the 
hyperfibrinolytic FXIIIA 185 T-allele as a consequence of its both anti-
thrombophilic and pro-angiogenic effects. 3-5, 34, 35, 63, 64 Moreover, the 
present predictive findings prospectively indicate the possibility to re-
evaluate the suitability of the previous notions regarding the optimized 
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laser-light dose of PDT-V. 7, 65-67 Currently, the socio-economic burden 
related to the treatment of neovascular AMD represents a very important 
puzzle, leading to increased health resource utilization and high societal 
costs. 68 Incongruously, as a consequence of both individual and racial 
PDT-V-efficacy variability, 6, 7, 20-24 there is a great interest in proposing 
the intravitreal anti-angiogenic treatments of CNV 4, 69 without 
considering a crucial bias that could be occurred during the definition of 
the parameters for the application of verteporfin therapy. In fact, this 
standardized procedure has been delineated after phase I/II clinical trials, 
conducted on a rather low number of patients who underwent PDT-V 
with different treatment regimens, which overlooked that the different 
coagulation-balance genetic backgrounds of each treated patient can 
significantly influence the final PDT-V effectiveness. 65-67 
Hypothetically, the ideal PDT-V may be accomplished differentiating the 
laser-light dose on the basis of the individual pro- and anti-thrombotic 
diatheses. In view of this innovative exploratory attitude, verteporfin 
therapy, anticipated by the intravitreal injection of an anti-VEGF drug, 
might be performed in a customized manner, aimed to induce the 
definitive shutdown of subfoveal CNV minimizing the required number 
of therapeutic combined approaches, which should be characterized by 
an higher (i.e. 100-125 J/cm2) or lower (i.e. 50-75 J/cm2) PDT-V light 
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dose, respectively, in patients with hyperfibrinolytic or thrombophilic 
predisposition. 
The results of this retrospective study open a new scenario for the 
realization of prospective, randomized and controlled, pharmacogenetic 
trials, which are warranted to: i. improve the international guidelines for 
PDT-V application; ii. develop appropriate therapeutic strategies 
combining customized PDT-V and anti-VEGF compounds; iii. 
downgrade the socio-economic burden of the interventive planning for 
subfoveal CNV secondary to AMD. 
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- 1) che la copia della tesi depositata presso l’Università di Ferrara in formato cartaceo, è del tutto identica a quelle presentate 
in formato elettronico (CD-ROM, DVD), a quelle da inviare ai Commissari di esame finale e alla copia che produrrò in 
seduta d’esame finale. Di conseguenza va esclusa qualsiasi responsabilità dell’Ateneo stesso per quanto riguarda eventuali 
errori, imprecisioni o omissioni nei contenuti della tesi; -- 2) di prendere atto che la tesi in formato cartaceo è l’unica alla quale 
farà riferimento l’Università per rilasciare, a mia richiesta, la dichiarazione di conformità di eventuali copie; -- 3) che il 
contenuto e l’organizzazione della tesi è opera originale da me realizzata e non compromette in alcun modo i diritti di terzi, 
ivi compresi quelli relativi alla sicurezza dei dati personali; che pertanto l’Università è in ogni caso esente da responsabilità di 
qualsivoglia natura civile, amministrativa o penale e sarà da me tenuta indenne da qualsiasi richiesta o rivendicazione da parte 
di terzi; -- 4) che la tesi di dottorato non è il risultato di attività rientranti nella normativa sulla proprietà industriale, non è 
stata prodotta nell’ambito di progetti finanziati da soggetti pubblici o privati con vincoli alla divulgazione dei risultati, non è 
oggetto di eventuali registrazioni di tipo brevettale o di tutela. --- PER ACCETAZIONE DI QUANTO SOPRA 
RIPORTATO 
 
Firma Dottorando 
Ferrara, lì _31.01.2010__ 
Firma del Dottorando _________________________________ 
 
Firma Tutore 
Visto: Il Tutore 
Si approva 
Firma del Tutore _______________________________________ 
FORMAZIONE POSTLAUREA 
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